Es gab 50 kürzliche Insider-Transaktionen für InMed Pharmaceuticals Inc. (INM), darunter 31 Käufe und 2 Verkäufe. Die gesamten Insider-Käufe beliefen sich auf $392.96K und die gesamten Insider-Verkäufe auf $18.54K.
Bedeutende Insider mit kürzlicher Aktivität umfassen Klompas Neil A, Hsu Eric C, Adams Eric A. Insider-Transaktionen können Einblicke geben, wie die Unternehmensführung die Bewertung und Zukunftsaussichten der Aktie einschätzt.
Insider-Transaktionen — INM
| Datum |
Name |
Funktion |
Transaktionsart |
Aktien |
Ø Preis |
Wert |
Gehaltene Aktien |
| 2025-12-19 |
Klompas Neil A |
Director |
RSU-Zuteilung |
1,750 |
$1.29 |
$2.26K |
5,250 |
| 2025-12-19 |
Hsu Eric C |
Sr. VP, Pre-clinical Res/dev |
RSU-Zuteilung |
13,000 |
$1.29 |
$16.77K |
18,280 |
| 2025-12-19 |
Adams Eric A |
President & CEO |
RSU-Zuteilung |
35,000 |
$1.29 |
$45.15K |
49,050 |
| 2025-12-19 |
Woudenberg Michael |
Chief Operating Officer |
RSU-Zuteilung |
18,000 |
$1.29 |
$23.22K |
25,445 |
| 2025-12-19 |
Hull Andrew |
Director |
RSU-Zuteilung |
1,750 |
$1.29 |
$2.26K |
2,711 |
| 2025-12-19 |
Johnson Shane Aaron |
Sr VP & General Manager |
RSU-Zuteilung |
8,500 |
$1.29 |
$10.97K |
12,400 |
| 2025-12-19 |
Lemerond Nicole |
Director |
RSU-Zuteilung |
1,750 |
$1.29 |
$2.26K |
2,725 |
| 2025-12-19 |
Jagpal Netta |
Chief Financial Officer |
RSU-Zuteilung |
18,000 |
$1.29 |
$23.22K |
24,250 |
| 2025-12-19 |
Bathery John Steven |
Director |
RSU-Zuteilung |
1,750 |
$1.29 |
$2.26K |
5,250 |
| 2025-12-15 |
Hsu Eric C |
Sr. VP, Pre-clinical Res/dev |
Option verfallen |
70 |
$1,397.97 |
$97.86K |
5,280 |
| 2025-12-15 |
Adams Eric A |
President & CEO |
Option verfallen |
250 |
$1,397.97 |
$349.49K |
14,050 |
| 2025-12-15 |
Woudenberg Michael |
Chief Operating Officer |
Option verfallen |
60 |
$1,397.97 |
$83.88K |
7,445 |
| 2025-12-15 |
Hull Andrew |
Director |
Option verfallen |
14 |
$1,397.97 |
$19.57K |
961 |
| 2025-10-17 |
Klompas Neil A |
Director |
RSU-Zuteilung |
3,500 |
$2.10 |
$7.35K |
3,500 |
| 2025-10-14 |
Bathery John Steven |
Director |
Unbekannt |
3,500 |
$2.10 |
$7.35K |
- |
| 2025-01-11 |
Hull Andrew |
Director |
Option verfallen |
2 |
$2,860.21 |
$5.72K |
975 |
| 2024-12-20 |
Grove Janet P |
Director |
RSU-Zuteilung |
550 |
$4.14 |
$2.28K |
975 |
| 2024-12-20 |
Baldasare Bryan T |
Director |
RSU-Zuteilung |
550 |
$4.14 |
$2.28K |
975 |
| 2024-12-20 |
Hsu Eric C |
Sr. VP, Pre-clinical Res/dev |
RSU-Zuteilung |
2,750 |
$4.14 |
$11.39K |
5,350 |
| 2024-12-20 |
Adams Eric A |
President & CEO |
RSU-Zuteilung |
6,250 |
$4.14 |
$25.88K |
14,300 |
| 2024-12-20 |
Woudenberg Michael |
Chief Operating Officer |
RSU-Zuteilung |
3,750 |
$4.14 |
$15.53K |
7,505 |
| 2024-12-20 |
Hull Andrew |
Director |
RSU-Zuteilung |
550 |
$4.14 |
$2.28K |
977 |
| 2024-12-20 |
Johnson Shane Aaron |
Sr VP & General Manager |
RSU-Zuteilung |
1,500 |
$4.14 |
$6.21K |
3,900 |
| 2024-12-20 |
Lemerond Nicole |
Director |
RSU-Zuteilung |
550 |
$4.14 |
$2.28K |
975 |
| 2024-12-20 |
Jagpal Netta |
Chief Financial Officer |
RSU-Zuteilung |
3,750 |
$4.14 |
$15.53K |
6,250 |
| 2024-10-09 |
Klompas Neil A |
Director |
Unbekannt |
- |
- |
- |
- |
| 2024-07-31 |
Mancini Alexandra Diane Janet |
Other: Consultant |
Informierter Verkauf |
240 |
$0.18 |
$42.31 |
- |
| 2024-05-27 |
Hsu Eric C |
Sr. VP, Pre-clinical Res/dev |
Option verfallen |
545 |
$263.18 |
$143.43K |
52,000 |
| 2024-05-27 |
Adams Eric A |
President & CEO |
Option verfallen |
1,139 |
$263.18 |
$299.76K |
161,000 |
| 2024-05-27 |
Woudenberg Michael |
Chief Operating Officer |
Option verfallen |
394 |
$263.18 |
$103.69K |
75,100 |
| 2024-03-04 |
Hsu Eric C |
Sr. VP, Pre-clinical Res/dev |
Option verfallen |
309 |
$364.72 |
$112.7K |
52,545 |
| 2024-02-21 |
Hull Andrew |
Director |
Informierter Kauf |
37,500 |
$0.39 |
$14.63K |
38,258 |
| 2024-02-20 |
Adams Eric A |
President & CEO |
Informierter Kauf |
41,600 |
$0.36 |
$14.92K |
43,959 |
| 2024-02-20 |
Jagpal Netta |
Chief Financial Officer |
Veräußerung |
50,000 |
$0.37 |
$18.5K |
- |
| 2024-01-21 |
Mancini Alexandra Diane Janet |
Sr VP, Clinical Reg Affairs |
Option verfallen |
121 |
$312.73 |
$37.84K |
52,485 |
| 2024-01-14 |
Hull Andrew |
Director |
Option verfallen |
42 |
$307.01 |
$12.89K |
8,542 |
| 2023-12-23 |
Grove Janet P |
Director |
RSU-Zuteilung |
7,100 |
$0.37 |
$2.63K |
8,500 |
| 2023-12-23 |
Tegge Jonathan |
Interim CFO |
RSU-Zuteilung |
30,000 |
$0.37 |
$11.1K |
31,400 |
| 2023-12-23 |
Baldasare Bryan T |
Director |
RSU-Zuteilung |
7,100 |
$0.37 |
$2.63K |
8,500 |
| 2023-12-23 |
Hsu Eric C |
Sr. VP, Pre-clinical Res/dev |
RSU-Zuteilung |
45,000 |
$0.37 |
$16.65K |
52,854 |
| 2023-12-23 |
Adams Eric A |
President & CEO |
RSU-Zuteilung |
136,000 |
$0.37 |
$50.32K |
162,139 |
| 2023-12-23 |
Woudenberg Michael |
Chief Operating Officer |
RSU-Zuteilung |
65,000 |
$0.37 |
$24.05K |
75,494 |
| 2023-12-23 |
Mancini Alexandra Diane Janet |
Sr VP, Clinical Reg Affairs |
RSU-Zuteilung |
45,000 |
$0.37 |
$16.65K |
52,606 |
| 2023-12-23 |
Hull Andrew |
Director |
RSU-Zuteilung |
7,100 |
$0.37 |
$2.63K |
8,584 |
| 2023-12-23 |
Johnson Shane Aaron |
Sr VP & General Manager |
RSU-Zuteilung |
40,000 |
$0.37 |
$14.8K |
48,000 |
| 2023-12-23 |
Lemerond Nicole |
Director |
RSU-Zuteilung |
7,100 |
$0.37 |
$2.63K |
8,500 |
| 2023-12-05 |
Woudenberg Michael |
Chief Operating Officer |
Option verfallen |
848 |
$270.36 |
$229.27K |
10,494 |
| 2023-08-31 |
Hsu Eric C |
Sr. VP, Pre-clinical Res/dev |
Option verfallen |
327 |
$499.96 |
$163.49K |
7,854 |
| 2023-05-16 |
Hsu Eric C |
Sr. VP, Pre-clinical Res/dev |
Option verfallen |
152 |
$623.93 |
$94.84K |
8,181 |
| 2023-05-16 |
Adams Eric A |
President & CEO |
Option verfallen |
1,818 |
$623.93 |
$1.13M |
26,139 |
■ Informativ — Transaktion am offenen Markt (bedeutendste)
■ Nicht-informativ (Kauf) — Vergütung, Optionsausübung, Wandlung
■ Nicht-informativ (Verkauf) — Quellensteuer, Verkauf bei Vesting
■ Neutral — Schenkung, Treuhand, Verfall
